MedTrace Logo

Post-market Clinical Follow-up Plan of StypCel™ Absorbable Hemostat

NCT07199439 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 108

Last updated 2025-09-30

No results posted yet for this study

Summary

This study is a post-market clinical follow-up (PMCF) plan for the StypCel™ Absorbable Hemostat, a medical device used to control bleeding during neurosurgery. The study include 108 patients . The aim of the study is to furtherly assess the safety and performance of the device under the real-word setting

Conditions

  • Neurosurgery

Sponsors & Collaborators

  • MDCECRO LLC

    collaborator NETWORK

  • Medprin Regenerative Medical Technologies Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Kaspars Auslands, Dr. · Riga's East Clinical University Hospital Riga, Latvia

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-23
Primary Completion
2023-04-25
Completion
2024-10-15

Countries

  • Latvia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07199439 on ClinicalTrials.gov